Signal Advisors Wealth LLC Purchases 2,492 Shares of Stryker Corporation $SYK

Signal Advisors Wealth LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 89.7% in the 3rd quarter, Holdings Channel.com reports. The firm owned 5,270 shares of the medical technology company’s stock after purchasing an additional 2,492 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Stryker were worth $1,948,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. L. Roy Papp & Associates LLP raised its position in Stryker by 1.7% in the third quarter. L. Roy Papp & Associates LLP now owns 63,998 shares of the medical technology company’s stock worth $23,658,000 after acquiring an additional 1,088 shares during the period. Shelton Wealth Management LLC grew its position in shares of Stryker by 8.9% during the 3rd quarter. Shelton Wealth Management LLC now owns 2,972 shares of the medical technology company’s stock valued at $1,099,000 after acquiring an additional 242 shares during the period. Astoria Portfolio Advisors LLC. increased its stake in shares of Stryker by 2.3% in the 3rd quarter. Astoria Portfolio Advisors LLC. now owns 2,363 shares of the medical technology company’s stock worth $887,000 after purchasing an additional 54 shares in the last quarter. Central Bank & Trust Co. raised its holdings in Stryker by 7.6% in the 3rd quarter. Central Bank & Trust Co. now owns 12,541 shares of the medical technology company’s stock worth $4,636,000 after purchasing an additional 883 shares during the period. Finally, Perkins Coie Trust Co lifted its position in Stryker by 4.2% during the third quarter. Perkins Coie Trust Co now owns 11,183 shares of the medical technology company’s stock valued at $4,134,000 after purchasing an additional 446 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the sale, the chief financial officer directly owned 6,694 shares in the company, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 522,118 shares of company stock worth $185,381,932 in the last 90 days. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Up 0.6%

NYSE SYK opened at $355.21 on Friday. The stock’s 50 day moving average is $365.26 and its 200 day moving average is $377.51. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a market cap of $135.84 billion, a PE ratio of 46.68, a P/E/G ratio of 2.50 and a beta of 0.89.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same period last year, the firm posted $2.87 EPS. The company’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be issued a $0.88 dividend. The ex-dividend date is Wednesday, December 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. Stryker’s payout ratio is presently 44.15%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Truist Financial cut their price target on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday. Wells Fargo & Company boosted their price objective on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a report on Monday. Royal Bank Of Canada restated an “outperform” rating and set a $435.00 target price on shares of Stryker in a research note on Friday, November 14th. Finally, BTIG Research reiterated a “buy” rating and issued a $410.00 price target on shares of Stryker in a research report on Friday, November 14th. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $431.84.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.